CommercialCoverageMedium impact
08.00.45e, Eptinezumab-jjmr (VYEPTI™)
Independence Blue Cross·Neurology, Family Medicine, Internal Medicine·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
The policy for Eptinezumab-jjmr (VYEPTI™), a migraine prevention medication, has been updated with a reissue effective May 28, 2025. This appears to be a commercial insurance policy update that may affect coverage, prior authorization, or billing requirements for this specific drug.
Action Required
By May 28, 2025: Billing team should review the complete updated policy 08.00.45e for Eptinezumab-jjmr (VYEPTI™) at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing procedures. Update billing system and provider workflows accordingly based on the specific policy changes detailed in the full document.